Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Caracciolo

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Contributions to Nephrology|December 18, 2004
Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemiaCorrado Tarella, Davide Bono, Manuela Zanni, et al.
Cancers|April 3, 2021
Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' HeelDaniele Caracciolo, Caterina Riillo, Maria Teresa Di Martino, et al.
Reviews on Recent Clinical Trials|January 27, 2026
Endoscopic Progression of Gastric DLBCL in an HIV-Positive Patient: A Case Report and Literature ReviewGiuseppe Quintieri, Alessandro Corea, Carmen Colaci, et al.
Current Cancer Drug Targets|April 1, 2017
Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma TreatmentCirino Botta, Maria Cuce, Daniele Caracciolo, et al.
International Journal of Cancer|May 9, 2020
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatmentDaniele Caracciolo, Caterina Riillo, Mariamena Arbitrio, et al.
Molecular Therapy. Nucleic Acids|March 9, 2020
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley RatsMaria Teresa Di Martino, Mariamena Arbitrio, Daniele Caracciolo, et al.
Current Drug Targets|July 10, 2013
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenarioMarco Rossi, Nicola Amodio, M T Di Martino, et al.
Expert Opinion on Therapeutic Targets|March 10, 2016
Mir-221/222 are promising targets for innovative anticancer therapyMaria Teresa Di Martino, Marco Rossi, Daniele Caracciolo, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 13, 2021
Tools in Pharmacogenomics Biomarker Identification for Cancer PatientsFrancesca Scionti, Maria Teresa Di Martino, Daniele Caracciolo, et al.
Journal of Hematology & Oncology|May 10, 2018
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approachesNicola Amodio, Lavinia Raimondi, Giada Juli, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Contributions to Nephrology|December 18, 2004
Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemiaCorrado Tarella, Davide Bono, Manuela Zanni, et al.
Cancers|April 3, 2021
Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' HeelDaniele Caracciolo, Caterina Riillo, Maria Teresa Di Martino, et al.
Reviews on Recent Clinical Trials|January 27, 2026
Endoscopic Progression of Gastric DLBCL in an HIV-Positive Patient: A Case Report and Literature ReviewGiuseppe Quintieri, Alessandro Corea, Carmen Colaci, et al.
Current Cancer Drug Targets|April 1, 2017
Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma TreatmentCirino Botta, Maria Cuce, Daniele Caracciolo, et al.
International Journal of Cancer|May 9, 2020
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatmentDaniele Caracciolo, Caterina Riillo, Mariamena Arbitrio, et al.
Molecular Therapy. Nucleic Acids|March 9, 2020
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley RatsMaria Teresa Di Martino, Mariamena Arbitrio, Daniele Caracciolo, et al.
Current Drug Targets|July 10, 2013
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenarioMarco Rossi, Nicola Amodio, M T Di Martino, et al.
Expert Opinion on Therapeutic Targets|March 10, 2016
Mir-221/222 are promising targets for innovative anticancer therapyMaria Teresa Di Martino, Marco Rossi, Daniele Caracciolo, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 13, 2021
Tools in Pharmacogenomics Biomarker Identification for Cancer PatientsFrancesca Scionti, Maria Teresa Di Martino, Daniele Caracciolo, et al.
Journal of Hematology & Oncology|May 10, 2018
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approachesNicola Amodio, Lavinia Raimondi, Giada Juli, et al.
Pageof 8